
    
      The study consists in comparing thalidomide to placebo in skin sarcoidosis. Patients with
      sarcoidosis not necessitating a high-dose corticosteroid regimen, and assessable skin
      lesions, are eligible. They are randomized and receive either thalidomide or placebo for 3
      months. Then they are given Thalidomide for a 3-month open-label period.
    
  